Studies | Study population | Language | Reference standard | Interval between repeated tests | Age | Sample | Sample size | Diabetes | |||
---|---|---|---|---|---|---|---|---|---|---|---|
TP‡‡ | FP | FN | TN | ||||||||
Wei et al. 2011 | ACS* | English | WHO¶1999 (2hOGTT**+FBG††) | >1 week | 65.6 | Plasma | 94 | 23 | 4 | 0 | 67 |
Ilany et al. 2011 | ACS | English | Unknown (2hOGTT+FBG) | 3-24 months | 57 | Plasma | 29 | 0 | 10 | 1 | 18 |
Bronisz et al. 2011 | STEMI†| English | WHO1999 (2hOGTT) | 3 months | 56.5 | Plasma | 200 | 8 | 20 | 2 | 170 |
Jimenez-Navarro et al. 2010 | PCI‡ (ACS 80%) | English | WHO1999 (2hOGTT) | 1 months | 60.8 | Capillary | 88 | 9 | 21 | 7 | 51 |
Lewczuk et al. 2009 | ACS | Polish | Unknown (2hOGTT+FBG) | 12 months | 51.9 | Plasma | 69 | 14 | 3 | 5 | 47 |
Knudsen et al. 2009 | STEMI | English | WHO1999 (2hOGTT+FBG) | 3 months | 58 | Plasma | 201 | 5 | 17 | 5 | 174 |
Srinivas-Shankar et al. 2008 | NSTEMI | English | WHO1999 (2hOGTT+FBG) | 3 months | 65 | Plasma | 49 | 3 | 3 | 2 | 41 |
Lankisch et al. 2008 | AMI§ | English | WHO1999 (2hOGTT+FBG) | 3 months | 62.7 | Plasma | 62 | 11 | 8 | 8 | 35 |
Choi et al. 2005 | AMI | English | WHO1999 (2hOGTT+FBG) | 3 months | 60.1 | Plasma | 30 | 7 | 3 | 2 | 18 |
Tenerz et al. 2003 | AMI | English | WHO1999 (2hOGTT+FBG) | 3 months | 63.2 | Capillary | 142 | 25 | 22 | 10 | 85 |
Liu et al. 2007 | General population | Chinese | ADA#2003 (2hOGTT+FBG) | 2-3 weeks | NA | Plasma | 259 | 30 | 17 | 8 | 204 |
Eschwege et al. 2001 | General population | English | WHO1999 (2hOGTT+FBG) | 30 months | 50 | Plasma | 5400 | 105 | 102 | 171 | 5022 |
De Vegt et al. 2000 | General population | English | WHO1985 (2hOGTT+FBG) | 2-6 weeks | 61.7 | Plasma | 1109 | 85 | 25 | 31 | 968 |
Ko et al. 1998 | General population | English | WHO1985 (2hOGTT+FBG) | 6 weeks | 41 | Plasma | 212 | 24 | 17 | 56 | 115 |
Farrer et al. 1995 | 3 months post-elective CABG|| | English | WHO1985 (2hOGTT+FBG) | 10 days | 56.8 | Plasma | 81 | 9 | 5 | 3 | 64 |